Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401461 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31720042 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL16000770 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL8130019 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL24579257 | 0.95 | CASP3 (0.50) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL14326310 | 0.95 | CASP3 (0.50) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31720053 | 0.95 | CASP3 (0.50) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL16000769 | 0.95 | CASP3 (0.50) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL28414499 | 0.91 | KMT2A (0.51) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL21187795 | 0.90 | KMT2A (0.56) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217577-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| EP-1572669-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-14 | — | — | EP | disclosed |
| US-6924396-B2 | α-haloenamine reagents | PHARMACIA CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| WO-2004048345-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| EP-1421056-A1 | (ALPHA)-HALOENAMINE REAGENTS | Pharmacia Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040092770-A1 | Alpha-haloenamine reagents | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6677487-B2 | COMBINING A TERTIARY AMIDE WITH A PENTAVALENT PHOSPHOROUS HALIDE IN A SOLVENT TO FORM AN ALPHA - HALOIMINIUM SALT AND CONVERTING THE ALPHA -HALOIMINIUM SALT TO THE ALPHA -HALOENAMINE WITH A BASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030080320-A1 | Alpha- haloenamine reagents | PHARMACIA CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003020684-A1 | (ALPHA)-HALOENAMINE REAGENTS | PHARMACIA CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030080320-A1 | Alpha- haloenamine reagents | HNMT, HDHD5, NISCH | KMT2A 749/4885CASP3 4861/4885EPHX2 390/4885 |
| US-20040092770-A1 | Alpha-haloenamine reagents | HNMT, HDHD5, NISCH | KMT2A 749/4885CASP3 4861/4885EPHX2 390/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | KMT2A 4176/4885CASP3 549/4885EPHX2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.